Resource Page

COMPARATIVE ANALYSIS OF CONJUNCTIVAL FLORA IN ADULT DIABETICS AND NON-DIABETICS AT UNIVERSITY OF ABUJA TEACHING HOSPITAL, GWAGWALADA, ABUJA, NIGERIA

Email:
Supervisor: DR. MUHAMMADU RILWAN CHIROMA AND DR. YUNUSA THAHIRU
Faculty: OPHTHALMOLOGY
Institution of Training:
Month: 5
Year: 2018

Abstract

AIM AND OBJECTIVES: This study aimed at comparing the conjunctival flora of adult diabetics with age and gender-matched controls; to correlate glycaemic status to isolated flora, and to determine their sensitivity pattern to antimicrobials. MATERIALS AND METHODS: One hundred and thirty-five consecutively consenting diabetics and controls attending the diabetic clinic and eye clinic of the University of Abuja Teaching Hospital (UATH), Gwagwalada were recruited within a duration of 5 months. .Conjunctival swabs taken from the patients were seeded on Chocolate, MacConkey and Sabouraud Dextrose agar plates. Gram staining of swabs was done and antibiotic sensitivity tested with Cefuroxime Ciprofloxacin, Ofloxacin, Imipenem, Levofloxacin, Ceftriaxone, Amikacin, Ceftazidime, Chloramphenicol, Gentamicin, and Penicillin. The data was analysed using Statistical Package for Social Sciences (SPSS) version 20. RESULTS: Positive conjunctival cultures were seen in diabetic patients (29.6%) compared to non diabetic (4.4 %) individuals (P=0.001).Organisms isolated in the diabetics were, Klebsiella pnemoniae Enterococcus faecalis, Staph aureus, Serrentia mercences, Strep.spp, and Citrobacter spp. Klebsiella pnemoniae was the predominantly isolated(21.7%). Ten (7.4%) of the diabetics had Candida albicans. Twenty (28.6%) of the seventy diabetics with poor glycaemic control had positive cultures. There was no correlation between glycaemic status and positive culture. Thirty-one (34.4%) of the 90 diabetics on oral hypoglycaemic agents, and three (18.7%) of those on insulin, had positive culture, (P=0.780). Isolated organisms were sensitive to Ceftazidime, Levofloxacin, Chloramphenicol and Amoxicillin, but poorly sensitive to Cefuroxime.

© 2024 NPMCN, All Rights Reserved
Powered by: